Nucleome Therapeutics
Biotechnology company decoding the dark matter of the human genome
Nucleome Therapeutics has raised €38M across 1 funding round from 5 investors, most recently a Series A round in Oct 2022. Based in Oxford, UK; active in Healthtech. Data as of 28 Oct 2026.
Oxford, UKwww.nucleome.com ↗
Total raised
€38M
€38,351,401
Funding rounds
1
Investors
5
distinct backers
Active since
2022-10
latest 2022-10
Funding by year
EUR raised per yearNucleome Therapeutics — funding by year — interactive chart.
Data table
| Nucleome Therapeutics — funding by year | |
|---|---|
| 2022 | €38M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-10-19 | Series A | €38M | British Patient Capital,Johnson & Johnson Innovation – JJDC,M Ventures,Oxford Science Enterprises,Pfizer Ventures | View deal → |
Investors
5Related news
- Nucleome Therapeutics Raises £37.5M in Series A Financingfinsmes.com · 2022-10
Similar companies
same sector or countryGlobal coverage: FundingData